We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

Q1 2025 Management View CEO Rob Davis highlighted the progress in commercialized medicines and vaccines, emphasizing the strength of newer product launches such as WINREVAIR and CAPVAXIVE. Revenue for ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

Merck (NYSE:MRK) experienced a 2.98% share price increase over the past week, during which several key developments occurred. The company reaffirmed its 2025 financial guidance, despite a slight ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

Merck & Co. has won approval from the European Commission of its Capvaxive pneumococcal disease vaccine for adults. The Rahway, N.J., drugmaker on Wednesday said the approval covers the 21-valent ...